Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

CLEVELAND, Jan. 28, 2011 /PRNewswire-USNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Critical Limb Ischemia (CLI). The FDA Investigational Device Exemption (IDE 14522) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) in improving perfusion in ischemic tissue in affected limbs of patients with CLI who are not eligible for revascularization surgery.

(Logo: http://photos.prnewswire.com/prnh/20100624/ALOGO)

The Magellan technology combines a rapid bedside tissue concentration device and sterile surgical disposables that produce platelet rich plasma from blood and bone marrow aspirations in approximately 15 minutes and was FDA approved through the 510(k) process for use as deemed appropriate by surgeons. The Magellan MAR01™ technology enables the rapid "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells, commonly viewed as key components in tissue repair. The company is developing MAR01™ for use as a clinical treatment for Critical Limb Ischemia, and plans to initiate additional clinical trials evaluating MAR01™ in cardiovascular disease, and the clinical setting of orthopedics and tissue repair during 2011.

Patient enrollment for the phase I safety study will begin immediately at The Ohio State University Medical Center (as the first clinical site), under the direction of Dr. Michael Go, Assistant Professor of Surgery in the Division
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, applauds ... for taking a strong position in opposition to ... July 27, 2014 publication.  The New York Times ... articles this week exploring the issue called "High ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... Call Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, March ... today reported on its corporate progress and financial results ... a very productive 2008 and are looking forward to an equally ... are on track to be in Phase 3 testing in all ...
... announces that its lead compound for inhibition of tau ... has been recognized as the most potent inhibitor of ... to date. Mutations of this gene are believed ... frequent cause of Parkinson,s Disease.TauTaTis, lead compound is a ...
... Traceability Down to the Unit Level to Secure Products and ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX Security™, a ... provider, today announced the availability of its new comprehensive technology ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:7/29/2014)... Helping people recover from the debilitating effects of ... requires deep knowledge of neurophysiology as well as ... options and outcomes has been the primary focus ... biomedical engineering, since he joined the NJIT faculty ... whose significance is underscored by substantial funding from ...
(Date:7/29/2014)... Dentistry (UM SOD) and Medicine (UM SOM) jointly ... $10.7 million grant award from the National Institute ... National Institutes of Health to study the causes, ... grant, which renews a previous $12 million five-year ... the research by studying chlamydial and gonorrheal diseases ...
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Unique images bring fossil insects back to life 2
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
MAGP-2 (C-19)...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
TGF-beta 2 MAb (Clone 8607)...
Biology Products: